TY - JOUR
T1 - Sandwich and half-sandwich derivatives of platensimycin
T2 - Synthesis and biological evaluation
AU - Patra, Malay
AU - Gasser, Gilles
AU - Wenzel, Michaela
AU - Merz, Klaus
AU - Bandow, Julia E.
AU - Metzler-Nolte, Nils
PY - 2012/8/27
Y1 - 2012/8/27
N2 - The multistep synthesis and biological evaluation of five structurally diverse, chiral and achiral CpMn(CO) 3 (4, 7 and 8), (η 6-arene)Cr(CO) 3 (5), and [3]ferrocenophane-1-one (6) containing platensimycin (1) derivatives are described in this report. The structures were inspired by the antibiotic platensimycin. All the chiral compounds presented in this report are racemates. The new compounds were unambiguously characterized by 1H and 13C NMR spectroscopy, mass spectrometry, IR spectroscopy, and elemental analysis and in certain cases by X-ray crystallography (4, 16, 18, and 29). The antibacterial and antitumor activity of selected derivatives was tested. Molecular modeling suggests that the derivatives described here may well fit into the active site of the FabF enzyme, which is the biological target of platensimycin. Hence, the antimicrobial activities of our new bioorganometallices 4-8 and the protected amide intermediates 15, 17, 18, 23, 28, 29, and 31 were tested against various Gram-positive and Gram-negative bacterial strains. However, all compounds were inactive up to concentrations of 180 μg/mL. The cytotoxicity of compounds 4 and 6 and the protected amide intermediates 15, 17, 18, 23, 28, 29, and 31 was tested against HepG2 and PT45 mammalian cancer cell lines. Surprisingly, all compounds containing a trimethylsilylethyl ester functionality at the aromatic ring (17, 23, 29, and 31) displayed rather high cytotoxicity between 2 and 9 μM.
AB - The multistep synthesis and biological evaluation of five structurally diverse, chiral and achiral CpMn(CO) 3 (4, 7 and 8), (η 6-arene)Cr(CO) 3 (5), and [3]ferrocenophane-1-one (6) containing platensimycin (1) derivatives are described in this report. The structures were inspired by the antibiotic platensimycin. All the chiral compounds presented in this report are racemates. The new compounds were unambiguously characterized by 1H and 13C NMR spectroscopy, mass spectrometry, IR spectroscopy, and elemental analysis and in certain cases by X-ray crystallography (4, 16, 18, and 29). The antibacterial and antitumor activity of selected derivatives was tested. Molecular modeling suggests that the derivatives described here may well fit into the active site of the FabF enzyme, which is the biological target of platensimycin. Hence, the antimicrobial activities of our new bioorganometallices 4-8 and the protected amide intermediates 15, 17, 18, 23, 28, 29, and 31 were tested against various Gram-positive and Gram-negative bacterial strains. However, all compounds were inactive up to concentrations of 180 μg/mL. The cytotoxicity of compounds 4 and 6 and the protected amide intermediates 15, 17, 18, 23, 28, 29, and 31 was tested against HepG2 and PT45 mammalian cancer cell lines. Surprisingly, all compounds containing a trimethylsilylethyl ester functionality at the aromatic ring (17, 23, 29, and 31) displayed rather high cytotoxicity between 2 and 9 μM.
UR - http://www.scopus.com/inward/record.url?scp=84865479497&partnerID=8YFLogxK
U2 - 10.1021/om201146c
DO - 10.1021/om201146c
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84865479497
SN - 0276-7333
VL - 31
SP - 5760
EP - 5771
JO - Organometallics
JF - Organometallics
IS - 16
ER -